Generic Name and Formulations:
Dextranomer microspheres 50mg/mL viscous gel in stabilized hyaluronic acid 15mg/mL carrier gel; implant for submucosal inj.
Valeant Pharmaceuticals, Inc
Indications for DEFLUX:
Vesicoureteral reflux (VUR) grades II–IV in children.
<1yr: not recommended. ≥1yr: see literature. Must use Deflux metal needle for administration. Inject submucosally in urinary bladder near the ureteral orifice.
Non-functional kidney. Hutch diverticulum. Ureterocele. Active voiding dysfunction. Ongoing UTI.
Do not inject intravascularly. Must be administered by qualified surgeon experienced in the use of cystoscope and trained in subureteric injection procedures. Use of >6mL (3mL at each ureteral orifice) at same treatment session: not recommended. Treatment of duplex systems has not been studied. Ureters with grossly dilated orifices. Infection and bleeding risks associated with cystoscopic procedure.
UTI, ureteral dilatation, nausea, vomiting, abdominal pain.
Single-use syringe (1mL)—1
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Bone Mineral Density Loss Eventually Stabilizes in Men With Type 1 Diabetes
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women
- FDA Approves First Mobile App for Use in Preventing Pregnancy
- Hypothyroidism Predicts Atrial Tachyarrhythmia After AF Catheter Ablation
- Treating Painful Diabetic Peripheral Neuropathy With Electroacupuncture